Skip to main content
SpringerLink
Log in

Phase II new drug trials in soft tissue sarcomas

  • Chapter
Clinical Management of Soft Tissue Sarcomas

Part of the book series: Cancer Treatment and Research ((CTAR,volume 29))

Abstract

As stated in chapter 6, doxorubicin remains the most active single chemother-apeutic agent in the treatment of metastatic soft tissue sarcomas. Approximately 25% of the patients treated with Doxorubicin will have a clinical response [1–5]. This was demonstrated with an interval of ten years in the USA [2] and Europe [4, 5]. A steep dose response curve documented in several series [2, 5] led to the recommendation to give the drug in a dose just tolerated by the bone marrow. Further studies with combinations in which DTIC, Vincristine, Cyclophosphamide and/or Actinomycin D were included, depicted, however not in randomized trials, a survival advantage for responders to the combinations. Median survivals of 15 months versus 8 months were reported [6–8]. Alterations in the basic CYVADIC regimen (Table 1) have been conducted in an effort to increase response and survival and to reduce toxicity [9–11] but offered no advantage over the conventional 5-day regimen. The last study [11] however revealed that the performance status of the patients was the major prognostic determinant for response. This could also explain the wide differences in response rates reported in several series. The only progress with the combinations was the observation that in a subgroup of patients the application of surgery could render these patients free of disease and a survival advantage was observed [12]. Considering this minimal advantage with the combination it is not surprising that several cooperative groups — ECOG and EORTC — have continued to use single-agent Adriamycin as their ‘standard’ of comparison, for first line treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Blum, R. H.: An overview of studies with Adriamycin (NSC 123127) in the United States. Cancer Chemother. Rep., 6: 247–251, 1975.

    Google Scholar 

  2. O’Bryan, R. M., Baker, L. H., Gottlieb, J. E., Rivkin, S. E., Balcerzak, S. P., Grumet, G. N., Salmon, S. E., Moon, T. E. and Hoogstraten, B.: Dose response evaluation of Adriamycin in human neoplasia. Cancer, 39: 1940–1948, 1977.

    Article  PubMed  Google Scholar 

  3. Schoenfeld, D. A., Rosenbaum, C., Horton, J., Wolter, J. M., Falkson, G. and DeConti, R. C: A comparison of Adriamycin versus vincristine and Adriamycin, and cyclophosphamide versus vincristine, actinomycin D, and cyclophosphamide for advanced sarcoma. Cancer, 50: 2757–2762, 1982.

    Article  PubMed  CAS  Google Scholar 

  4. Bramwell, V. H. C., Mouridsen, H. T., Mulder, J. H., Somers, R., Van Oosterom, A. T., San-toro, A., Thomas, D., Sylvester, R., Markham, D.: Carminomycin vs. adriamycin in advanced soft tissue sarcomas; an EORTC randomized phase II study. Eur. J. Cancer Clin. Oncol. 19: 1097–1104, 1983.

    Article  PubMed  CAS  Google Scholar 

  5. Mouridsen, H. T., Somers, R., Santoro, A., Mulder, J. H., Bramwell, V., Van Oosterom, A. T., Sylvester, R., Thomas, D., Pinedo, H. M.: Doxorubicin vs epirubicin in advanced soft tissue sarcomas. An EORTC randomized phase II study. In: Advances in anthracycline chemotherapy: Epirubicin, edited by Bonadonna, G., Masson Milano, 95–103, 1984.

    Google Scholar 

  6. Gottlieb, J. A., Benjamin, R. S., Baker, L. H., O’Bryan, R. M., Rivkin, S. E. and Bodey, G. P.: Role of DTIC (NSC 45388) in the chemotherapy of sarcomas. Cancer Treatm. Rep., 60: 199–203, 1976.

    CAS  Google Scholar 

  7. Benjamin, R. S., Gottlieb, J. A., Baker, L. H. and Sinkovics, J. G.: CYVADIC vs. CYVADACT — A randomized trial of cyclophosphamide, vincristine, Adriamycin, plus dacarbazine, or actinomycin-D in metastatic sarcomas. Proc. AACR and ASCO, 17: 256, 1976.

    Google Scholar 

  8. Yap, B. S., Baker, L. H., Sinkovics, J. G., Rivkin, S. E., Bottomley, R., Thigpen, T., Burgess, M. A., Benjamin, R. S. and Bodey, G. P.: Cyclophosphamide, vincristine, Adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treatm. Rep., 64: 93–98, 1980.

    CAS  Google Scholar 

  9. Benjamin, R. S. and Yap, B. S.: Infusion chemotherapy for soft tissue sarcomas. In: Soft Tissue Sarcomas, edited by Baker, L. H., Martinus Nijhoff Publishers, The Hague, The Netherlands, 1983.

    Google Scholar 

  10. Bernard, S. A., Capizzi, R. L., Rudnick, S. A., Tremont, S. J. and Raymond, R. N.: A one-day combination chemotherapy (CYVADIC) regimen in soft tissue sarcomas. Proc. ASCO, 1: 170, 1982.

    Google Scholar 

  11. Pinedo, H. M., Bramwell, V. H. C., Mouridsen, H. T., Somers, R., Vendrik, C. P. J., Santoro, A., Buesa, J., Wagener, Th., van Oosterom, A. T., van Unnik, J. A. M., Sylvester, R., de Pauw, M., Thomas, D. and Bonadonna, G.: Cyvadic in Advanced Soft Tissue Sarcoma: A randomized study comparing two schedules. Cancer 53: 1825–1832, 1984.

    Article  PubMed  CAS  Google Scholar 

  12. Yap, B. S., Sinkovics, J. G., Burgess, M. A., Benjamin, R. S. and Bodey, G. P.: The curability of advanced soft tissue sarcomas in adults with chemotherapy. Proc. ASCO, 2: 239, 1983.

    Google Scholar 

  13. Samson, M. K.: Phase II New Drug Trials in soft tissue sarcomas. In: Soft Tissue Sarcomas, edited by Baker, L. H.; Martinus Nijhoff Publishers, The Hague, The Netherlands: 135–140, 1983.

    Google Scholar 

  14. Saiki, J. H., Baker, L. H., Stephens, R. L., Fabian, C. J., Kraut, E. H. and Fletcher, W. S.: Gallium Nitrate in Advanced Soft Tissue and Bone Sarcomas: A Southwest Oncology Group Study. Cancer Treatm. Rep., 66: 1673–1674, 1982.

    CAS  Google Scholar 

  15. Vaughn, C. B., McKelvey, E., Balcerzak, S. P., Loh, K., Stephens, R. and Baker, L. H.: High-Dose Methotrexate With Leucovorin Rescue Plus Vincristine in Advanced Sarcoma: A Southwest Oncology Group Study. Cancer Treatm. Rep. 68: 409–410, 1984.

    CAS  Google Scholar 

  16. Bull, F. E., Von Hoff, D. D., Balcerzak, S. P., Stephens, R. L. and Panettiere, F. J.: Phase II Trial of Mitoxantrone in Advanced Sarcomas: A Southwest Oncology Group Study. Cancer Treatm. Rep. 69: 231–233, 1985.

    CAS  Google Scholar 

  17. Smith, I. E.: Mitoxantrone (novantrone): A review of experimental and early clinical studies. Cancer Treatm. Rev. 10: 103–115, 1983.

    Article  CAS  Google Scholar 

  18. Zidar, B., Baker, L., Rivkin, S., Balcerzak, S., Stephens, R.: A Phase II Study of Aziridinylbenzoquinone (AZQ) in advanced soft tissue and bony sarcoma. A Southwest Oncology Group (SWOG) Study. Proc. ASCO, 4: 130, 1985.

    Google Scholar 

  19. Borden, E. C., Ash, A., Enterline, H. T., Rosenbaum, Ch., Laucius, J. F., Paul, A. R., Falk-son, G., Lerner, H.: Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. Am. J. Clin. Oncol. (CCT) 5: 417–420, 1982.

    Article  CAS  Google Scholar 

  20. Thigpen, T., Shingleton, H., Homesley, H. and Blessing, J., for the Gynecologic Oncology Group: Phase II trial of Cis-Diamminedichloroplatinum (DDP) in treatment of advanced or recurrent mixed mesodermal sarcoma of the uterus. Proc. ASCO, 1: 110, 1982.

    Google Scholar 

  21. Brenner, J., Magill, G. B., Sordillo, P. P., Cheng, E. W., Yagoda, A.: Phase II Trial of Cisplatin (CPDD) in Previously Treated Patients with Advanced Soft Tissue Sarcoma. Cancer 50: 2031–2033, 1982.

    Article  PubMed  CAS  Google Scholar 

  22. Samson, M. K., Baker, L. H., Benjamin, R. S., Lane, M., Plager, C.: Cisdichlorodiammineplatinum (II) in advanced soft tissue sarcomas: A Southwest Oncology Group Study. Cancer Treatm. Rep. 63: 2027–2029, 1979.

    CAS  Google Scholar 

  23. Bramwell, V. H. C., Brugarolas, A., Mouridsen, H. T., Cheix, F., de Jager, R., van Oosterom, A. T., Vendrik, C. P., Pinedo, H. M., Sylvester, R. and de Pauw, M.: EORTC phase II study of cisplatin in Cyvadic-resistant soft tissue sarcoma. Eur. J. Cancer 15: 1511–1513, 1979.

    PubMed  CAS  Google Scholar 

  24. Magill, G. B.: Personal Communication, 1985.

    Google Scholar 

  25. Welt, S., Magill, G. B., Sordillo, P. P., Cheng, E., Hakes, T., Wittes, R. E. and Yagoda, A.: Phase II Trial of VP-16-213 in adults with advanced soft tissue sarcomas. Proc. ASCO, 2: 234, 1983.

    Google Scholar 

  26. Magill, G. B., Brenner, J., Sordillo, P. P., Cheng, E., Welt, W. and Currie, V. E.: Phase II trials of Metoprine (DDMP) in pretreated adults with advanced soft tissue sarcomas. Proc. ASCO, 1: 22, 1982.

    Google Scholar 

  27. Raymond, V., Magill, G. B., Welt, S., Kruger, G., Sordillo, P. P., Cheng, E. and Young, C. W.: 4-Demethoxydaunorubicin (DMDR) in advanced soft tissue sarcomas (STS): A Phase II Study. Proc. ASCO, 2: 235, 1983.

    Google Scholar 

  28. Wissel, P., Magill, G., Raymond, V., Welt, S., Sordillo, P. P. and Cheng, E.: 4’Demethoxydaunorubicin (DMDR) in advanced soft tissue sarcomas: An update with emphasis on patients (PTS) without prior doxorubicin (DOX). Proc. ASCO 3: 259, 1984.

    Google Scholar 

  29. Wissel, P., Magill, G., Welt, S., O’Hehir, M., Sordillo, P. and Currie, V.: Phase II Trial of Lonidamine (l,-2,4-Dichlorophenyl)-lH-Indazol-3-Carbollytic Acid) (LON) in advanced soft tissue sarcomas. Proc. ASCO 3: 258, 1984.

    Google Scholar 

  30. Yap, B. S., Benjamin, R. S., Plager, C., Burgess, M. A., Papadopoulos, N. and Bodey, G. P.: A randomized study of continuous infusion vindesine versus vinblastine in adults with refractory metastatic sarcomas. Am. J. Clin. Oncol. (CCT) 6: 235–238, 1983.

    Article  CAS  Google Scholar 

  31. Papadopoulos, N. E. J., Tenney, D. M., Benjamin, R. S., Plager, C., Chawla, S. P., Yap, B. S., Bodey, G. P.: Phase II study of bisantrene in advanced sarcoma. Proc. ASCO 3: 264, 1984.

    Google Scholar 

  32. Kurzrock, R., Yap, B. S., Plager, C., Papadopoulos, N., Benjamin, R. S., Valdivieso, M., Bodey, G. P.: Phase II Evaluation of PALA in patients with refractory metastatic sarcomas. Am. J. Clin. Oncol. 7 (4): 305–307, 1984.

    Article  PubMed  CAS  Google Scholar 

  33. Bramwell, V., Van Oosterom, A. T., Mouridsen, H. T., Cheix, F., Somers, R., Thomas, D. and Rozencweig, M.: N-(Phosphonacetyl)-L-Aspartate (PALA) in advanced soft tissue sarcoma: A Phase II trial of the EORTC Soft Tissue Sarcoma Group. Eur. J. Cancer Clin. Oncol. 18 (1): 81–84, 1982.

    Article  PubMed  CAS  Google Scholar 

  34. Presant, C. A., Bartolucci, A. A.: Phase II evaluation of Chlorozotocin in metastatic sarcomas. Med. Pediatr. Oncol. 12: 25–27, 1984.

    Article  PubMed  CAS  Google Scholar 

  35. Mouridsen, H. T., Bramwell, V. H. C., Lacave, J., Metz, R., Vendrik, C. P. J., Hild, J., McCreanney, J. and Sylvester, R.: Treatment of advanced soft tissue sarcomas with chlorozotocin. A Phase II trial of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer Treatm. Rep.: 509–511, 1981.

    Google Scholar 

  36. Buesa, J. M., Mouridsen, H. T., Bonadonna, G., Somers, R., van Oosterom, A. T., Jasmin, G., Bramwell, V., Cortes Funes, H., Vendrik, C. P. J., Wagener, T. and Thomas, D.: Treatment of advanced soft tissue sarcomas with low dose Methotrexate. A Phase II trial of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer Treatm. Rep. 68: 683–684, 1984.

    CAS  Google Scholar 

  37. Van Oosterom, A. T., Santoro, A., Bramwell, V., Davy, M., Mouridsen, H. T., Thomas, D. and Sylvester, R.: Mitomycin C (MMC) in advanced soft tissue sarcoma: A Phase II Study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 21: 459–461, 1985.

    Article  PubMed  Google Scholar 

  38. Somers, R., Rouëssé, J., Van Oosterom, A. T. and Thomas, D.: Phase II study of Elliptinium in metastatic soft tissue sarcoma. Eur. J. Cancer and Clin. Oncol. 21: 591–593, 1985.

    Article  CAS  Google Scholar 

  39. Harris, J. E., Das Gupta, T. and Vogelzang, N.: Treatment of soft tissue sarcoma with fibroblast interferon (HuIFN-B)-American Cancer Society/Illinois Cancer Council Study — Final Report. Proc. ASCO 4: 222, 1985.

    Google Scholar 

  40. Stuart-Harris, R. C., Harper, P. G., Parsons, C. A., Kaye, S.B., Mooney, C. A., Gowing, N. F. and Wiltshaw, E.: High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother. Pharmacol. 11: 65–72, 1983.

    Article  Google Scholar 

  41. Scheulen, M. E., Niederle, N., Bremer, K., Schütte, J. and Seeber, S.: Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: Results of a clinical phase II-study with 151 patients. Cancer Treatm. Rev. 10, (Suppl. A): 93–101, 1983.

    Article  Google Scholar 

  42. Bramwell, V., Mouridsen, H., Santoro, A., Blackledge, G., Somers, R., Thomas, D., Sylvester, R., Bush, H.: Cyclophosphamide (CP) vs Ifosfamide (IF): A randomized phase II trial in adult soft tissue sarcoma (STS). Preliminary report of EORTC Soft Tissue and Bone Sarcoma Group. Proc. ASCO 4: 143, 1985.

    Google Scholar 

  43. Magrath, I. T., Sandlund, J. T., Rayner, A., Rosenberg, S. A., Arasi, V. and Miser, J. S.: Treatment of recurrent sarcomas with Ifosfamide (IF). Proc. ASCO 4: 136, 1985.

    Google Scholar 

  44. Antman, K. H., Montella, D., Rosenbaum, Ch. and Schwen, M.: A Phase II Trial of Ifosfamide with Mesna in Previously Treated Metastatic Sarcoma. Cancer Treatm. Rep., 69: 499–504, 1985.

    CAS  Google Scholar 

  45. Schütte, J., Dombernowsky, P., Santoro, A., Steward, W., Mouridsen, H. T., Somers, R., van Oosterom, A. T., Blackledge, G., Thomas, D. and Sylvester, R.: Adriamycine (A) and Ifosfamide (I), A New Effective Combination in Advanced Soft Tissue Sarcoma. Proc. ASCO 5: 145, 1986.

    Google Scholar 

  46. Van Oosterom, A. T., Bramwell, V. H. C., Mouridsen, H. T., Somers, R., Santoro, A., Buesa, J., Vendrik, C. P., Rouëssé, J., Dombernowsky, P., Pinedo, H. M., Thomas, D. and Sylvester, R.: Review of the EORTC Soft Tissue and Bone Sarcoma Groups’ Phase II Studies in Advanced Soft tissue sarcomas, Ed. J. van Unnik and A. T. van Oosterom, EORTC Monograph, Raven Press New York, 161–167, 1986.

    Google Scholar 

Download references

Authors
  1. Allan T. Van Oosterom
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology, Free University Hospital, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands

    H. M. Pinedo

  2. Department of Oncology, The Dr. Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands

    J. Verweij

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Van Oosterom, A.T. (1986). Phase II new drug trials in soft tissue sarcomas. In: Pinedo, H.M., Verweij, J. (eds) Clinical Management of Soft Tissue Sarcomas. Cancer Treatment and Research, vol 29. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2319-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2319-8_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9426-9

  • Online ISBN: 978-1-4613-2319-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation